SARS-COV-2 is the human corona virus that has been creating a global anomaly and responsible for the world wide pandemic. The main purpose of this article is to corelate with a solution following the paths of interferon effectiveness for the infection vaccination following the liposome mediated drug delivery system for the infected, non-infected SARS-COV-2 patients. SARS-COV-2 shows most sensitivity to interferon specially the IFNβ subtype. Due to the special characteristics and anti-viral effects in the context of any emerging viral epidemics as the first line of detectors and defence, the type 1 interferons (IFN1) are taken into consideration. Now for installation of the medication our goal is to a) installing the interferon by following the interferon cascade mechanism as vaccination of healthy individuals b) installation of interferon effectiveness by following the Liposome mediated drug delivery system. By approaching these 2 procedures our motive is to make it effective against COVID-19/20.